The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.

Lilly partners with Kumquat to discover small molecule IO drug. Kite, Appia Bio collaborate on allogeneic cell therapies. AstraZeneca and Regeneron pursue novel metabolic therapies targeting GPR75. Lexeo and Stelios merge to focus on gene therapies for rare cardiovascular indications.

China's top regulator grants approvals to a record number of novel drugs, including multiple oncology products from domestic companies, which are increasingly shifting to innovation, supported by positive regulatory changes over the past few years. 

Cost concerns and an increased number of potential entrants will dominate the annual adjustments to China's the national reimbursement drug list, with regulators moving to manage companies' expectations.